Cumberland Pharmaceuticals Receives Vizient Contract for Vibativ 

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, now provides Vibativ (telavancin) 4-Vial Starter Pak through a new contract with Vizient, a provider-driven healthcare performance improvement company.

Through this agreement, Vizient members now have increased access to Vibativ’s new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy.

Vibativ is an FDA-approved injectable antibiotic indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including MRSA.

Vizient serves over 65% of the nation’s acute care providers, including 97% of academic medical centers and 35% of the non-acute market.

In addition to the Vibativ 4-Vial Starter Pak, the Vibativ 12-vial carton is also available to Vizient provider clients through several distribution channels.

“We’re pleased to expand availability of the new Vibativ 4-Vial Starter Pak for Vizient-contracted providers, supporting the cost-efficient delivery of our potent antibiotic in hospitals, infusion centers, and outpatient centers nationwide,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.